SureTrader Advertisement Advertisement Advertisement
Home > Boards > US OTC > Biotechs >

Intellect Neurosciences, Inc. (ILNS)

Add ILNS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Jumpinjackas, montanus, AlaskaBushMan, dbing
Search This Board:
Last Post: 11/26/2015 1:07:31 AM - Followers: 187 - Board type: Free - Posts Today: 0


Intellect Neurosciences Inc. (OTCBB: ILNS) is a biopharmaceutical company engaged in the discovery and development of a new breed of innovative "disease-modifying" therapeutic drugs that are designed to slow, arrest and ultimately prevent Alzheimer's disease and other serious neurodegenerative disorders. 

Intellect is focused on neurodegenerative conditions collectively known as proteinopathies such as Alzheimer's, Parkinson's and Huntington disease.  Proteinopathies are caused by amyloidogenic proteins, such as amyloid beta, tau, alpha synuclein and Huntingtin.  Intellect is the first company to develop antibody drug conjugates (ADCs) in which amyloid clearing antibodies are empowered by chemically linking them to molecules that offer neuroprotection, creating a single drug.  The use of ADCs is one way in which Intellect is developing more effective drugs with the recognition that monotherapy may not be effective enough in treating the complex nature of proteinopathies. 

A second approach being pioneered by Intellect, also based on this idea and specifically focused on Alzheimer's disease, is a bi-specific vaccine that targets both beta amyloid and a pathogenic form of tau protein.  In contrast to antibodies that only target beta amyloid and have not yet proven their ability to treat mild to moderate Alzheimer's disease, the dual target vaccine being developed by Intellect has the potential to be used both prophylactically in presymptomatic patients and therapeutically in patients that are symptomatic.

Intellect Neurosciences has its origins in some of the earliest pioneering work that stimulated the development of the potential disease-modifying monoclonal antibodies that several global pharmaceutical companies have been testing as treatments for Alzheimer's disease. The intellectual property resulting from the discovery of how such antibodies could be used as treatments predates competitive strategies such that the pharmaceutical companies developing those drugs, purchased licenses to the technology from Intellect. The company remains ahead of the curve with respect to next-generation therapies, as it has developed multiple distinctive platform technologies that are generating drug candidates for a wide variety of diseases. 

The company developed OX1, a multimodal antioxidant molecule, through preclinical and human safety trials before licensing the program to ViroPharma.  ViroPharma has said it plans to enter Phase 2 clinical trials in patients with Friedreich's Ataxia, an orphan indication, in 2013.  Intellect could receive in excess of $100 million in milestone payments from ViroPharma and, if approved, royalties from sales over many years.

Intellect's preclinical R&D pipeline is based on two proprietary platform technologies, CONJUMAB-A and RECALL-VAX and includes the following drug candidates: 

CONJUMAB-A: Empowered Antibodies for the Treatment of Proteinopathies

N01-OX2 is a first-in-class ADC.  It is a humanized monoclonal antibody specific for beta amyloid protein that is empowered to deliver on-site neuroprotection by its conjugation to melatonin.  The goal of N01-OX2 is to reduce the oxidative stress that leads to cellular inflammation and damage.  N01-OX2 is being developed for the treatment of age-related macular degeneration (AMD), the leading cause of blindness in people over the age of 55. AMD therapies generate $4 billion annually, even though the few approved treatments don't cure the disease and offer only modest improvements in vision for most patients.  N01-OX2 also has potential applications for diabetic retinopathy, glaucoma, traumatic brain injury and Alzheimer's disease.

T01-OX2 is an ADC comprised of a monoclonal antibody selective for oligomeric toxic forms of tau protein and is empowered with neuroprotection by its conjugation to melatonin.  T01-OX2 is expected to reduce tau pathology and has potential for the treatment of Alzheimer's disease, Frontotemporal dementia and also has potential applications to treat ophthalmology indications.

RECALL VAX:  A chimeric peptide vaccine comprised of a human B cell epitope linked to a bacterial T cell epitope to produce highly specific vaccines against one or more amyloidogenic proteins.

RV03 is a first-in-class bi-specific vaccine targeting both beta amyloid and delta tau.  Delta tau is a shorter form of the tau protein.  It is especially toxic to nerve cells and precedes the formation of neurofibrillary tangles.  RV03 has potential for the treatment of Alzheimer's disease and Frontotemporal dementia.

Intellect's preclinical R&D pipeline is based on four proprietary platform technologies: ANTISENILINÒ, CONJUMAB™, OLIGOTOPE™ and RECALL-VAX™

ANTISENILIN®: Free-end Specific Amyloid Beta Antibodies for Treatment of AD
IN-N01 is a humanized a high-affinity, stabilized, IgG4 therapeutic antibody that binds the amino terminus of amyloid beta without binding to the amyloid precursor protein (APP).
Antibodies exist in several isoforms; IgG1 antibodies have the strongest potential to induce inflammation while IgG4 has the lowest potential. IN-N01 is designed to promote the clearance of monomeric, oligomeric and plaque forms of amyloid beta, which accumulate in the brains of Alzheimer's patients or following traumatic brain injury and in the retina of the eye in patients with age-related macular degeneration, diabetic neuropathy and glaucoma.
CONJUMAB™: Empowered Antibodies for the Treatment of Proteinopathies
CONJUMAB-A is a first-in-class antibody drug conjugate for treatment of proteinopathies. IN-N01 has been empowered to deliver on-site neuroprotection by its conjugation to melatonin. Melatonin is a potent free radical scavenger and is an inhibitor of beta amyloid aggregation and previously shown to counteract the neurotoxicity associated with amyloid beta. Compounds based upon CONJUMAB-A are designed to reduce the oxidative stress and promote clearance of beta amyloid that is central to cellular inflammation and damage.
CONJUMAB-A is being developed for the treatment of age-related macular degeneration (AMD), the leading cause of blindness in people over the age of 55. CONJUMAB-A also has potential applications for diabetic retinopathy, glaucoma, traumatic brain injury, and Alzheimer's disease.
OLIGOTOPE™: Protein oligomer selective antibodies and methods of making them using chemically cross-linked stabilized aggregates as immunogens

TOC-1, our first compound utilizing the OLIOGOTOPE platform, is a murine monoclonal antibody selective for neurotoxic tau oligomers or aggregates considered to be the earliest pathogenic form of tau. Intellect plans to test TOC-01 as potential therapeutic for Alzheimer's disease and other tauopathies such as Frontotemporal dementia.
TauC3 specifically targets the neoepitope that is formed following cleavage of intact tau protein by proteolytic enzymes known as "executioner" caspases. This pathological process is stimulated by an accumulation of amyloid beta in the brain of Alzheimer's patients. It is believed that the smaller cleaved tau, referred to as delta tau, is especially toxic and prone to form tangles inside nerve cells and occurs early in the pathogenesis of the disease so antibody-mediated removal of delta tau would be expected to prevent the irreversible damage to nerve cells.
RECALL VAX™: Chimeric peptide vaccine platform incorporating bacterial and human epitopes to target neoepitopes in pathological proteins
RV03, our first compound generated on the RECALL-VAX platform, is a first-in-class bi-specific vaccine targeting both beta amyloid and delta tau. Delta tau is a shorter form of the tau protein. It is especially toxic to nerve cells and precedes the formation of neurofibrillary tangles. RV03 has potential for the treatment of Alzheimer's disease and Frontotemporal dementias.




Intellect Neurosciences has two preclinical programs it is developing internally.

One program under the RECALL-VAX platform has yielded two AD vaccine drug candidates, RV01 and RV02. RECALL-VAX™ has the potential to delay or prevent the development of Alzheimer's in those who are at risk by stimulating patients' immune systems to produce antibodies that clear amyloid betas and prevent further accumulation and deposition. Many view a vaccine of this nature, which is analogous to a flu shot, as the ultimate quest in Alzheimer's research.

Additionally,  CONJUMAB-A is Intellect's newly introduced platform technology for a novel class of therapeutics for treatment of Alzheimer's disease and other proteinopathies based on antibody-drug conjugates (ADCs).  The new ADC- based technology has the potential to improve on current methods of passive immunotherapy by increasing clearance of amyloid proteins while delivering potent cytoprotective molecules to sites of damage in the brain and other organs.  CONJUMAB-A is designed to reduce inflammation caused by amyloidosis while avoiding vasogenic edema, a side effect of plaque dissolution that occurs in some patients.   The company's lead CONJUMAB-A candidate is IN-N01-OX2, a non-activating, stabilized IgG4 humanized antibody specific for beta amyloid protein conjugated to melatonin, which is a naturally occurring molecule with potent anti-oxidant and anti-fibrillogenic properties. 

The Company has applied for a patent for its CONJUMAB-A technology. Intellect has the exclusively license to certain patents granted by the USPTO to NYU School of Medicine and the University of South Alabama Research Foundation specifically covering the use of melatonin for the treatment of Alzheimer's disease and other types of amyloidosis. The CONJUMAB-A platform is applicable to a broad range of diseases including, Alzheimer's, Parkinson's, Huntington's, Age-Related Macular Degeneration, Glaucoma, Cerebral Angiopathy, Frontotemporal Dementia, Progressive Supranuclear Palsy, Pick's disease, Cortical Basal Degeneration and Peripheral Amyloidosis.


Jan. 16, 2014, 3:20 a.m. EST

Intellect Neurosciences, Inc. Announces Positive Top Line Data Showing Proof of Concept in a Preclinical Alzheimer's Model for Its TauC3 Monoclonal Antibody Indicating its Potential to be Disease Modifying

Study indicates potential for TauC3 to be disease-modifying.




ENGLEWOOD CLIFFS, N.J., Jan 16, 2014 (GLOBE NEWSWIRE via COMTEX) -- via PRWEB - Intellect Neurosciences, Inc. ILNS +1.37% , a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic and diagnostic agents for the treatment of Alzheimer's and other neurological diseases, today announced it obtained proof of concept in a preclinical Alzheimer's model for its TauC3 monoclonal antibody indicating its potential to be disease modifying. The study was conducted in collaboration with University of California, Irvine's Dr. Frank LaFerla, Chancellor's Professor and Chair, Neurobiology and Behavior School of Biological Sciences, Director, Institute for Memory Impairments and Neurological Disorders as well as Dr. Kim Green and his team. The data showed that the TauC3 antibody effectively engaged the target and reduced certain phosphorylated pathological forms of Tau indicating that the treatment with the peripherally administered antibody had an effect in the brain and is able to be disease modifying. The investigators aim to publish the full data in a peer-reviewed scientific journal.

TauC3 specifically targets a fragment of Tau protein that is believed to result from beta-amyloid ("Aβ") induced cleavage of full length Tau by apoptotic caspase enzymes, early in the disease process leading to neuronal loss. The truncated tau ("delta tau", aka "TauC3" fragment) displays increased rates and extents of polymerization in vitro compared with wild-type full-length tau, suggesting a role for tau truncation in neurofibrillary tangle formation. Recently Professor Bradley Hyman's laboratory at Harvard Medical School also showed a critical role of this fragment in oligomeric Aβ-induced synaptic loss near Aβ plaques in the AD brain providing a mechanistic link between oligomeric Aβ and tau in AD (Polydoro et al., AAIC 2013, P2-048).

"We are gratified by this compelling proof of concept data independently generated by our collaborators at the University of California, Irvine." said Mr. Elliot Maza, a director of Intellect Neurosciences. "These important new data and growing strength of our revitalized patent portfolio, including the recent patent Allowance from the USPTO in relation to the TOC-1 monoclonal antibody targeting oligomeric tau, underscore our leadership in this area and should attract significant renewed interest from the pharmaceutical industry".

Intellect Neurosciences holds worldwide development and commercialization rights to TauC3 under an exclusive license agreement with Northwestern University. Also, Intellect owns pending patent applications relating to antibodies targeting fragments of Tau in the brain for treatment of Alzheimer's and other tauopathies (e.g. Chain, 2011: Treatment of Tauopathies, WO 2012/106363 published November 15, 2012).

About Intellect Neurosciences

Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases, with a specific focus on proteinopathies. Intellect's pipeline includes, antibodies and neuroprotective antibody drug conjugates. For more information, please visit .

Safe Harbor Statements Regarding Forward Looking Statements

The statements in this release and oral statements made by representatives of Intellect Neurosciences relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those discussed in Intellect's Annual Report on Form 10-K (file no. 333-128226) filed on October 15, 2013 and Quarterly Report on Form 10-Q (file no. 333-128226), filed on November 19, 2013.

Contact: (at)intellectns(dot)com

This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit


Intellect Neurosciences Obtains Patent Allowance From the United States Patent and Trademark Office in Relation to Its TOC-1 Monoclonal Antibody Selective for Pre-Fibrillar Tau Aggregates

Published: November 14, 2013

NEW YORK, Nov. 14, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc.(OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic and diagnostic agents for the treatment of Alzheimer's and other neurological diseases, today announced it obtained a Notice of Allowance from the United States Patent and Trademark Office (USPTO). The patent allowance is in relation to TOC-1, a monoclonal antibody that selectively binds neurotoxic pre-fibrillar tau aggregates which are important pathological components in Alzheimer's disease (AD) and other neurodegenerative tauopathies. Intellect previously obtained development and commercialization rights to TOC-1 under an exclusive license agreement withNorthwestern University.  

New findings regarding the antibody were recently published in the Journal of Alzheimer's Disease in a paper titled, "TOC1: Characterization of a Selective Oligomeric Tau Antibody" written by Lester Binder, Ph.D., the Abbott Laboratories, Duane and Susan Burnham Research Professor of Genetic and Molecular Medicine, at Northwestern University. These data underscore its potential as a powerful biochemical tool that can be used to better investigate the involvement of tau in neurodegenerative diseases.  

"The new patent allowance from the USPTO awarded to Intellect Neurosciences is of particular significance in view of the considerable attention being given to the important role of pre-fibrillar aggregated forms of tau in the pathogenesis of AD and other tauopathies such as cortico-basal ganglia degeneration and progressive supranuclear palsy," said Professor Moses V. Chao, Molecular Neurobiology Program Skirball Institute of Biomolecular Medicine NYU School of Medicine.  "TOC-1 reacts with brain pathology in each of these types of diseases and is undoubtedly an important biochemical tool that will be extremely helpful to academic and industry researchers". 

The Company is exploring ways to commercialize TOC-1, initially as an essential tool which is required for research, but also for further development clinically.

About Intellect Neurosciences

Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases, with a specific focus on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates. For more information, please





Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: March 4, 2013
Last updated: May 14, 2015
Last verified: May 2015


PRONUNCIATION poe nez' oo mab 
THERAPEUTIC CLAIM Treatment of Alzheimer’s disease 
1. Immunoglobulin G2, anti-(human ß-amyloid) (human-mouse monoclonal PF-04360365 
clone 9TL heavy chain), disulfide with human-mouse monoclonal PF-04360365 
clone 9TL light chain, dimer 
2. Immunoglobulin G2, anti-(human amyloid beta A4 protein (Alzheimer disease amyloid 
protein, ABPP, APPI, preA4, protease nexin-II)); humanized mouse monoclonal 
PF-04360365 clone 9TL des-442-lysine(CH3107-K)-[325-serine(CH299A>S),326- 
serine(CH2100P>S)]?2 heavy chain (130-219')-disulfide with humanized mouse 
monoclonal PF-04360365 clone 9TL ? light chain, dimer (218-218'':219-219'':222- 
MOLECULAR FORMULA C6552H10158N1730O2090S52 
TRADEMARK None as yet 
CODE DESIGNATION PF-04360365, RN-1219 




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ILNS News: Quarterly Report (10-q) 11/12/2015 06:01:19 PM
ILNS News: Current Report Filing (8-k) 10/26/2015 03:24:28 PM
ILNS News: Current Report Filing (8-k) 10/21/2015 01:33:57 PM
ILNS News: Annual Report (10-k) 10/14/2015 06:07:34 AM
ILNS News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 09/25/2015 05:19:23 PM
#18985  Sticky Note Ok its been along time that I spoke. itwillgetbetter 10/11/15 06:15:22 PM
#19253   I forgot when it comes to legal issues itwillgetbetter 11/26/15 01:07:31 AM
#19252   No LOL but I was notified today I'm itwillgetbetter 11/26/15 12:56:09 AM
#19251   Did you talk to our board of director(s) Jumpinjackas 11/25/15 10:49:31 PM
#19250   Did u ever get your shares that dissappeared? dbing 11/25/15 05:26:04 PM
#19249   Again a lot has changed regarding my financial itwillgetbetter 11/25/15 12:42:20 PM
#19248   I have high hopes and imo in a itwillgetbetter 11/25/15 12:25:07 PM
#19247   It's tempting to buy more here, but it's Jumpinjackas 11/25/15 10:47:53 AM
#19246   Around 30 , buy now at this low mkaiz 11/25/15 09:23:27 AM
#19245   You had recently advised against buying any shares Jumpinjackas 11/25/15 08:43:00 AM
#19244   What is your avg here? Jumpinjackas 11/25/15 08:41:10 AM
#19243   Started buying mine in Jan of 2010 sold mkaiz 11/25/15 08:17:43 AM
#19242   Im not sure why you all are trading tyfoidhana 11/24/15 08:55:13 PM
#19241   Me too. buckiii2 11/24/15 07:54:15 PM
#19240   Me as well!! john1045 11/24/15 04:51:48 PM
#19239   I would be more than happy to get Drs136 11/24/15 04:44:33 PM
#19238   Wait just a minute. I've been confident from itwillgetbetter 11/24/15 03:45:23 PM
#19237   There you go. Jumpinjackas 11/24/15 11:07:52 AM
#19236   I don't get you sometimes, you say Jumpinjackas 11/24/15 08:26:01 AM
#19235   Been drinking a lot but its not doom itwillgetbetter 11/24/15 03:22:43 AM
#19234   No Doom & Gloom just a guaranteed write tyfoidhana 11/23/15 09:48:51 PM
#19233   So much doom & gloom. TheSaint09 11/23/15 08:36:02 PM
#19232   Were all on the 10 year plan Drs136 11/23/15 06:01:06 PM
#19231   I stepped on that land mine in the itwillgetbetter 11/23/15 05:21:13 PM
#19230   Sorry, easy for me to say. If I'm Jumpinjackas 11/23/15 02:26:10 PM
#19229   I'll have to cut the grass several more times. buckiii2 11/23/15 02:22:06 PM
#19228   So, what's another 6 more mos. Jumpinjackas 11/23/15 02:21:21 PM
#19227   Patient. I been in this since 2010? buckiii2 11/23/15 02:05:16 PM
#19226   It can and it will. Be patient Jumpinjackas 11/23/15 01:29:19 PM
#19225   Can ILNS get a deal? buckiii2 11/23/15 01:08:22 PM
#19224   Surprised that results of the trial is not Jumpinjackas 11/23/15 10:32:18 AM
#19223   What's not true over a few days to itwillgetbetter 11/18/15 11:51:35 PM
#19222   Not true. They couldn't even get a million to Jumpinjackas 11/18/15 01:54:48 PM
#19221   LOL on what you said. Pretty funny cause itwillgetbetter 11/18/15 01:51:59 PM
#19220   I never spent time to find out whom itwillgetbetter 11/18/15 01:17:58 PM
#19219   I feel for them. They even spent Jumpinjackas 11/18/15 09:40:14 AM
#19218   Don't know the exact number but remember if itwillgetbetter 11/17/15 03:56:01 PM
#19217 I wonder how many shares they got Jumpinjackas 11/17/15 02:21:32 PM
#19216   I will try to help you and give itwillgetbetter 11/17/15 02:16:40 PM
#19215   Not many good trees left in North Dakota, AlaskaBushMan 11/17/15 08:40:12 AM
#19214   There is probably an nda that prevents him Jumpinjackas 11/17/15 07:38:28 AM
#19213   Here is what i don't get.... who are Jumpinjackas 11/17/15 02:31:08 AM
#19212   Not yet you are correct. You get the itwillgetbetter 11/16/15 10:19:47 PM
#19211   Except there is no liquidity as there is Jumpinjackas 11/16/15 08:16:20 PM
#19210   By the way I would love to be itwillgetbetter 11/16/15 06:08:03 PM
#19209   Pretty funny. Have you build a new tree itwillgetbetter 11/16/15 05:52:19 PM
#19208   No one commenting since the 10-Q? AlaskaBushMan 11/16/15 05:19:38 PM
#19207   Speaking to the choir. You missed the point. itwillgetbetter 11/11/15 01:12:28 PM
#19206   They can't sell anything as no one is Jumpinjackas 11/11/15 08:35:59 AM
#19205   Forget market cap. They are still even from itwillgetbetter 11/10/15 02:48:54 PM
#19204   $2.3867. And I'm even and out. Figure that Drs136 11/10/15 09:54:54 AM